Literature DB >> 10905494

Genotype/phenotype relationships in HNF-4alpha/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels.

D Q Shih1, H M Dansky, M Fleisher, G Assmann, S S Fajans, M Stoffel.   

Abstract

Hepatocyte nuclear factor (HNF)-4alpha is a transcription factor that plays an important role in regulation of gene expression in pancreatic beta-cells and in the liver. Heterozygous mutations in the HNF-4alpha gene are responsible for maturity-onset diabetes of the young 1 (MODY1), which is characterized by pancreatic beta-cell-deficient insulin secretion. HNF-4alpha is a major transcriptional regulator of many genes expressed in the liver. However, no liver defect has been identified in individuals with HNF-4alpha mutations. In this study, we have identified HNF-4alpha target genes that are mainly expressed in the liver, including alpha1-antitrypsin, alpha1-antichymotrypsin, alpha-fetal protein, ceruloplasmin, IGF binding protein 1, transferrin, apolipoprotein(AI) [apo(AI)], apo(AII), apo(B), and apo(CIII). Serum levels of these proteins and Lp(a) and triglycerides were measured in 24 members of the HNF-4alpha/MODY1 RW pedigree (Q268X mutation), including 12 diabetic patients with HNF-4alpha mutations (D-HNF4+/-), 6 nondiabetic subjects with HNF-4alpha mutations (N-HNF4+/-), 6 normal relatives (N-HNF4+/+), 6 unrelated normal matched control subjects (N-HNF4+/+), and 12 matched diabetic (non-MODY1-5) patients (D-HNF4+/+). Serum levels of apo(AII), apo(CIII), lipoprotein(a) [Lp(a)], and triglyceride were significantly reduced in HNF4+/- subjects (26.9, 19.8, 12.1, and 72.1 mg/dl, respectively) compared with HNF4+/+ subjects (37.4, 26.5, 45.2, and 124.2 mg/dl, respectively) (P = 0.00001, P = 0.01, P = 0.00006, and P = 0.000003, respectively). This reduction was not found when apo(AII), apo(CIII), Lp(a), and triglyceride levels were compared in D-HNF4+/- versus N-HNF4+/- or in D-HNF4+/+ versus N-HNF4+/+ subjects, which indicates that HNF-4alpha haploinsufficiency rather than hyperglycemia is the primary cause of decreased serum protein and triglyceride concentrations. Furthermore, we determined that genetic or environmental modifiers other than HNF-4alpha do not appear to contribute to the observed decrease of HNF-4alpha-regulated serum proteins. This study demonstrates that a heterozygous HNF-4alpha mutation leads to an HNF-4alpha-dependent hepatocyte secretory defect of liver-specific proteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10905494     DOI: 10.2337/diabetes.49.5.832

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  36 in total

1.  Hepatic hepatocyte nuclear factor 4α is essential for maintaining triglyceride and cholesterol homeostasis.

Authors:  Liya Yin; Huiyan Ma; Xuemei Ge; Peter A Edwards; Yanqiao Zhang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

2.  Phenotypic heterogeneity between different mutations of MODY subtypes and within MODY pedigrees.

Authors:  S S Fajans; G I Bell
Journal:  Diabetologia       Date:  2006-02-25       Impact factor: 10.122

3.  Dynamic regulation of Drosophila nuclear receptor activity in vivo.

Authors:  Laura Palanker; Aleksandar S Necakov; Heidi M Sampson; Ruoyu Ni; Chun Hu; Carl S Thummel; Henry M Krause
Journal:  Development       Date:  2006-08-16       Impact factor: 6.868

Review 4.  Molecular etiologies of MODY and other early-onset forms of diabetes.

Authors:  David Q Shih; Markus Stoffel
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

5.  Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.

Authors:  John S Millar; Katsunori Ikewaki; LeAnne T Bloedon; Megan L Wolfe; Philippe O Szapary; Daniel J Rader
Journal:  J Lipid Res       Date:  2010-10-22       Impact factor: 5.922

6.  Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs.

Authors:  Xuefen Xie; Hailing Liao; Huaixin Dang; Wei Pang; Youfei Guan; Xian Wang; John Y-J Shyy; Yi Zhu; Frances M Sladek
Journal:  Mol Endocrinol       Date:  2009-01-29

Review 7.  Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism.

Authors:  John Y L Chiang
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-02       Impact factor: 4.481

8.  Signalling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b.

Authors:  Soo-Hee Park; Christopher A Wiwi; David J Waxman
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

9.  Research resource: nuclear hormone receptor expression in the endocrine pancreas.

Authors:  Jen-Chieh Chuang; Ji-Young Cha; James C Garmey; Raghavendra G Mirmira; Joyce J Repa
Journal:  Mol Endocrinol       Date:  2008-07-31

10.  Molecular cloning and characterization of the human PED/PEA-15 gene promoter reveal antagonistic regulation by hepatocyte nuclear factor 4alpha and chicken ovalbumin upstream promoter transcription factor II.

Authors:  Paola Ungaro; Raffaele Teperino; Paola Mirra; Angela Cassese; Francesca Fiory; Giuseppe Perruolo; Claudia Miele; Markku Laakso; Pietro Formisano; Francesco Beguinot
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.